Roles of sex steroids and their receptors in the pathophysiology of hepatocellular carcinoma;Roles des steroides sexuels et de leurs recepteurs dans la physiopathologie du carcinome hepatocellulaire

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 1, 1998, Pages 73-86

  Clavière, Christophe ^a   Bronowicki, Jean Pierre ^a,b   Hudziak, Hervé ^a   Bigard, Marc André ^a   Gaucher, Pierre ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Androgens; Cirrhosis; Estrogens; Hepatocellular carcinoma; Hormonal receptors; Pathophysiology; Progesterone; Sex steroid hormones

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CYPROTERONE ACETATE; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; GONADORELIN DERIVATIVE; HORMONE RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; SEX HORMONE; STEROID; STEROID RECEPTOR;

HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER REGENERATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; ANIMAL; EXPERIMENTAL LIVER CIRRHOSIS; LIVER TUMOR; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GONADAL STEROID HORMONES; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; LIVER REGENERATION; RECEPTORS, STEROID; STEROIDS;

EID: 0031940535     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Nagasue N, Kohno H. Hepatocellular carcinoma and sex hormones. Hepatobiliary Surg 1992;6:1-6.
2. Ng IOL, Ng MMT, Lai ECS, Fan ST. Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer 1995;75:18-22.
3. Nagasue N, Galizia G, Yukaya H, Kohono H, Chang YC, Hayashi T, et al. Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepatogastroenterology 1989;36:379-83.
4. Lau WY, Leung WT, Ho S, Lam SK, Li CY, Johnson PJ, et al. Hepatocellular carcinoma during pregnancy and its comparison with other pregnancy-associated malignancies. Cancer 1995;75:2669-76.
5. Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973;2:926-9.
6. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976;9:470-1.
7. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992;15:948-63.
8. Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977;73:388-94.
9. Goldfarb G, Benhamou JP. Adénome du foie et hyperplasie nodulaire focale. Relation avec les contraceptifs oraux. Gastroenterol Clin Biol 1979;3:465-72.
10. Rabe T, Feldmann K, Grunwald K, Runnebaum B. Liver tumours in women on oral contraceptives. Lancet 1994;344:1568-9.
11. Vana J, Murphy GP, Aronoff BL, Baker HW. Primary liver tumors and oral contraceptives. JAMA 1977;238:2154-8.
12. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977;86:180-2.
13. Mariani AF, Linvingstone AS, Pereiras RV, Zuiden PEV, Schiff ER. Progressive enlargement of an hepatic cell adenoma. Gastroenterology 1979;77:1319-25.
14. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994;129:712-7.
15. Tao LC. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 1991;68:341-7.
16. Telsuk H, Lawrie J. Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981;105:296-7.
17. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993;67:635-7.
18. Valla D, Benhamou JP. Liver diseases related to oral contraceptives. Dig Dis 1988;6:76-88.
19. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986;292:1355-7.
20. Neuberger J, Nunnerley HB, Davis M, Portmann B, Laws JW, Williams R. Oral-contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis. Lancet 1980;1:273-6.
21. Terpstra OT, Ten Kate FJW, Van Urk H. Long-term survival after resection of a hepatocellular carcinoma with lymph nodes metastasis and discontinuation of oral contraceptives. Am J Gastroenterol 1984;79:474-8.
22. Boyd PR, Mark GJ. Multiple hepatic adenomas and a hepatocellular carcinoma in a man on oral methyl testosterone for eleven years. Cancer 1977;40:1765-70.
23. Bruguera M. Hepatoma associated with androgenic steroids. Lancet 1975;1:1295.
24. Farrell GC, Uren RF, Perkins KW, Joshua DE, Baird PJ, Kronenberg H. Androgen-induced hepatoma. Lancet 1975;1:430-2.
25. Frémond B, Jouan H, Sameh AH, Le Gall E, Bergeron C, Manac'h A, et al. Tumeurs du foie secondaires à l'androgénothérapie. A propos de 2 cas chez l'enfant. Chir Pediatr 1987;28:97-101.
26. Hernandez-Nieto L, Bruguera M, Bombi JA, Camacho L, Rozman C. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). Cancer 1977;40:1761-4.
27. Johnson FL, Lerner KG, Siegel M, Feagle JR, Majerus PW, Hartmann JR. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972;2:1273-6.
28. Johnson FL. Hepatoma associated with androgenic steroids. Lancet 1975;1:1294-5.
29. McCaugnan GW, Bilous MJ, Gallagher ND. Long term survival with tumor regression in androgen induced tumors. Cancer 1985;56:2622-6.
30. Ziegenfuss J, Charabasi R. Androgens and hepatocellular carcinoma. Lancet 1973;1:262.
31. Carrasco D, Prieto M, Pallard L, Moll JL, Cruz JM, Munoz C, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate. J Hepatol 1985;1:573-8.
32. Eagon PK, Porter LE, Francavilla A, Di Leo A, Van Thiel DH. Estrogen and androgen receptors in liver: their role in liver disease and regeneration. Semin Liver Dis 1985;5:59-69.
33. Kattan J, Spatz A, Culine S, Terrier-Lacombe MJ, Elias D, Droz JP. Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am J Clin Oncol 1994;17:390-2.
34. Watanabe S, Yamasaki S, Tanae A, Hibi I, Ad hoc Committee on Androcur Users, Honna T. Three cases of hepatocellullar carcinoma among cyproterone users. Lancet 1994;344:1567-8.
35. Rüdiger T, Beckmann W, Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet. 1995;345:452-3.
36. Buzzeli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without surimposed hepato-carcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol 1993;88:1744-8.
37. Conover CA, Baker BK, Bale LK, Clarkson JT, Liu F, Hintz RL. Human hepatoma cells synthetize and secrete insulin-like growth factor la prohormone under growth hormone control. Regul Pept 1993;48:1-8.
38. Pooie TM, Drinkwater NR. Strain dependent effects of sex hormones on hepatocarcinogenesis in mice. Carcinogenesis 1996;17:191-6.
39. Cameron RG, Imaida K, Tsuda H, Ito N. Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res 1982;42:2426-8.
40. Wanless IR, Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest 1982;46:313-20.
41. Yager JD, Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 1980;40:3680-5.
42. Coe JE, Ishak KG, Ross MJ. Estrogen induction of hepatocellular carcinomas in Armenian hamsters. Hepatology 1990;11:570-7.
43. Li JJ, Li SA. Estrogen carcinogenesis in hamster tissues: a critical review. Endocrine Rev 1990;11:524-30.
44. Eagon PK, Chandar N, Epley MJ, Elm MS, Brady EP, Rao KN. Di (2-ethyllhexyl) phtalate-induced changes in liver estrogen metabolism and hyperplasia. Int J Cancer 1994;58:736-43.
45. Krattenmacher R, Knauthe R, Parczyk K, Walker A, Hilgenfeldt U, Fritzmeier KH. Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. J Steroid Biochem Mol Biol 1994;48:207-14.
46. Murphy LJ, Friesen HG. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinology 1988;122:325-32.
47. Dubois V, Couissi D, Schonne E, Remade C, Trouet A. Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium. Eur J Biochem 1995;232:47-53.
48. Gabrielsson BG, Carmignac DF, Flavell DM, Robinson ICAF. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology 1995;136:209-17.
49. Hernandez ER. Regulation of the genes for insulin-like growth factor (IGF) I and II and their receptors by steroids and gonadotropins in the ovary. J Steroid Biochem Mol Biol 1995;53:219-21.
50. Halliwell B. Mechanisms involved in the generation of free radicals. Pathol Biol 1996;44:6-13.
51. Laval J. Role of DNA repair enzymes in the cellular resistance to oxidative stress. Pathol Biol 1996;44:14-24.
52. Gaziano JM, Hennekens CH. Update on dietary antioxidants and cancer. Pathol Biol 1996;44:42-5.
53. Gérard-Monnier D, Chaudière J. Métabolisme et fonction antioxydante du glutathion. Pathol Biol 1996;44:77-85.
54. Hambali Z, Ngah WZW, Wahid SA, Kadir KA. Effect of ovariectomy and sex hormone replacement on gluthatione and gluthatione-related enzymes in rat hepatocarcinogenesis. Pathology 1995;27:30-5.
55. Firminger HI, Reuber MD. Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in A times C rats fed N-2-fluorenyldiacetamide. J Natl Cancer Inst 1961;27:559-78.
56. Gupta S, Korula J. Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol 1988;10:651-4.
57. Taylor W, Snowball S. The effect of long-term administration of the methyltestosterone on the development of liver lesions in BALB/c mice. J Pathol 1984;143:211-8.
58. Vesselinovitch SD, Mihailovich N. The effect of gonadectomy on the development of hepatomas induced by urethan. Cancer Res 1967;27:1788-91.
59. Reuber MD. Importance of testes in induction of hyperplastic nodules, carcinomas, and cirrhosis of liver in A times C male rats ingesting 0.025 % N-2-fluorenyldiacetamide. J Natl Cancer Inst 1974;53:883-6.
60. Erdstein J, Wisebord S, Mishkin SY, Mishkin S. The effect of several sex steroid hormones on the growth rate of three Morris hepatoma tumor lines. Hepatology 1989;9:621-4.
61. Rao MS, Subbarao V, Yeldandi AV, Reddy JK. Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res 1992;52:2977-9.
62. Ostrowski JL, Ingleton PM, Underwood JCE, Parsons MA. Increased hepatic androgen receptor expression in female rats during diethylnitrosamine liver carcinogenesis. Gastroenterology 1988;94:1193-200.
63. Francavilla A, Gavaler JS, Makowka L, Barone M, Mazzaferro V, Ambrosino G, et al. Estradiol and testosterone levels in patients undergoing partial hepatectomy. A possible signal for hepatic regeneration ? Dig Dis Sci 1989;34:818-22.
64. Francavilla A, DiLeo A, Eagon PK, Wu SQ, Ove P, Van Thiel DH, et al. Regenerating rat liver: correlations between estrogen receptor localization and deoxyribonucleic acid synthesis. Gastroenterology 1984;86:552-7.
65. Fisher B, Gunduz N, Saffer EA, Zheng S. Relation of estrogen and its receptor to rat liver growth and regeneration. Cancer Res 1984;44:2410-5.
66. Francavilla A, Eagon PK, DiLeo A, Polimeno L, Panella C, Aquilino AM, et al. Sex hormone-related functions in regenerating male rat liver. Gastroenterology 1986;91:1263-70.
67. Francavilla A, Polimeno L, DiLeo A, Barone M, Ove P, Coetzee M, et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989;9:614-20.
68. Van Thiel DH, Stauber R, Gavaler JS, Francavilla A. Hepatic regeneration. Effects of age, sex hormone status, prolactin, and cyclosporine. Dig Dis Sci 1991;36:1309-12.
69. Leffert HL, Koch KS, Moran T, Rubalcava B. Hormonal control of rat liver regeneration. Gastroenterology 1979;76:1470-82.
70. Ni N, Yager JD. The co-mitogenic effects of various estrogens for TGF-α-induced DNA synthesis in cultured female rat hepatocytes. Cancer Lett 1994;84:133-40.
71. Noguchi S, Ohba Y, Oka T. Pretranslational enhancement of epidermal growth factor receptor by direct effect of testosterone in mouse liver. Endocrinology 1991;128:2141-8.
72. Becker U, Gluud C. Sex, sex hormones and chronic liver diseases. Dig Dis 1991;9:9-16.
73. Lester R, Eagon PK, Van Thiel DH. Feminization of the alcoholic: the estrogen/testosterone ratio (E/T). Gastroenterology 1979;76:415-7.
74. Guéchot J, Peigney N, Ballet F, Vaubourdolle M, Giboudeau J, Poupon R. Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology 1989;10;346-8.
75. Becker U. The influence of ethanol and liver disease on sex hormones and hepatic estrogen receptors in women. Acta Obstet Gynecol Scand 1994;73:437-8.
76. Kohigashi K, Fukuda Y, Imura H. Estrogen receptors in hepatocellular carcinoma: is endocrine therapy for hepatocellular carcinoma likely to be effective ? Gastroenterol Jpn 1987;22:322-30.
77. Gavaler JS, Van Thiel DH, Deal SR. Surgical risk in alcoholic cirrhotic postmenopausal women: prognostic value of levels of hormones. J Surg Oncol 1993;53 (suppl 3): 52-4.
78. 450 levels. Gastroenterology 1986;90:299-305.
79. 450 after portal bypass. Biochem Pharmacol 1994;48:701-8.
80. Farinati F, De Maria N, Marafin C, Faguioli S, Della Libera G, Naccarato R. Hepatocellular carcinoma in alcoholic cirrhosis: is sex imbalance a pathogenic factor ? Eur J Gastroenterol 1995;7:145-50.
81. Guéchot J, Peigney N, Ballet F, Vaubourdolle M, Giboudeau J, Poupon R. Sex imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer 1988;62:760-2.
82. Lampropoulou-Karatzas C, Goritsas P, Makri MG. Low serum testosterone: a special feature of hepatocellular carcinoma. Eur J Med 1993;2:23-7.
83. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993;53:790-4.
84. Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer 1995;63:491-3.
85. Iqbal MJ,Wilkinson ML, Forbes A, Corbishley TP, Williams R. Preponderance of serum and intra-hepatic 5α-dehydrotestosterone in males with hepatocellular carcinoma despite low circulating androgen levels. J Hepatol 1986;3:304-9.
86. Evans RM. The steroid and thyroid hormones receptor superfamily. Science 1988;240:889-95.
87. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human estrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320:134-9.
88. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;231:1150-4.
89. Newton CJ. Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells. J Steroid Biochem Mol Biol 1995;55:327-36.
90. Pavone-Macaluso M, Carruba G, Castagnetta L. Steroid receptors in prostate cancer tissues and cells: pathophysiology, problems in methodology, clinical value and controversial questions. Arch Esp Urol 1994;47:189-201.
91. Angrand PO. Les domaines de liaison de l'ADN des facteurs de transcription eucaryotes. Med Sci 1993;9:725-36.
92. Arnold SF, Obourn JD, Jaffe H, Notides AC. Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. J Steroid Biochem Mol Biol 1995;55:163-72.
93. Gronemeyer H. Control of transcription activation by steroid hormone receptors. FASEB J 1992;6:2524-9.
94. Touitou I, Maudelonde T. Récepteurs des hormones stéroïdes. Rev Prat (Paris) 1994;44:1294-7.
95. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86.
96. Davoodi F, Brenner RV, Evans SRT, Schumaker LM, Shabahang M, Nauta RJ, et al. Modulation of vitamin D receptor and estrogen receptor by 1,25(OH)2-vitamin D3 in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 1995;54:147-53.
97. Dellovade TL, Zhu YS, Pfaff DW. Potential interactions between estrogen receptor and thyroid receptors relevant for neuroendocrine systems. J Steroid Biochem Mol Biol 1995;53:27-31.
98. Eckert RL, Katzenellenbogen BS. Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 1982;42:139-44.
99. Green S. Modulation of estrogen receptor activity by estrogens and anti-oestrogens. J Steroid Biochem Mol Biol 1990;37:747-51.
100. Kendall ME, Rose DP. The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 1992;114:127-31.
101. Koritnik DR, Koshy A, Hoversland RC. 17 beta-estradiol treatment increases the levels of estrogen receptor and its mRNA in male rat liver. Steroids 1995;60:519-29.
102. Kraus WL, Weis KE, Katzenellenbogen BS. Inhibitory cross-talk between steroid hormone receptors: differencial targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 1995;15:1847-57.
103. Shan LX, Rodriguez MC, Janne OA. Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral prostate and seminal vesicles and in human hepatoma cells. Mol Endocrinol 1990;4:1636-46.
104. Wittliff JL. Steroid receptor interactions in breast carcinoma. Cancer 1980;46:2953-60.
105. Lahooti G, White R, Hoare SA, Rahman D, Pappin DJC, Parker MG. Identification of phosphorylation sites in the mouse oestrogen receptor. J Steroid Biochem Molec Biol 1995;55:305-15.
106. Yu L, Nagasue N, Makino Y, Nakamura T. Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas. J Hepatol 1995;22:295-302.
107. Francavilla A, Eagon PK, DiLeo A, Van Thiel DH, Panella C, Polimeno L, et al. Circadian rhythm of hepatic cytosolic and nuclear estrogen and androgen receptors. Gastroenterology 1986;91:182-8.
108. Daffada AAI, Dowsett M. Tissue-dependent expression of a novel splice variant of the human oestrogen receptor. J Steroid Biochem Mol Biol 1995;55:413-21.
109. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 1992;52:483-6.
110. Laudet V, Stéhelin D. Les récepteurs nucléaires. Pour la Science 1993;183:32-9.
111. Anolik JH, Klinge CM, Hilf R, Bambara RA. Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. Biochemistry 1995;34:2511-20.
112. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-8.
113. Catherine WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 1995;9:1053-63.
114. Robins DM, Scheller A, Adler AJ. Specific steroid response element from a nonspecific DNA element. J Steroid Biochem Mol Biol 1994;49:251-5.
115. Hendry LB, Mahesh VB. A putative step in steroid hormone action involves insertion of steroid ligands into DNA facilitated by receptor proteins. J Steroid Biochem Mol Biol 1995;55:173-83.
116. Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 1995;9:1053-63.
117. Daffada AAI, Johnston SRD, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995;55:288-93.
118. Fuqua SAW, Fitzgerald SD, Chamnes GC, Tandon AK, McDonnell DP, Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991;51:105-9.
119. Fuqua SAW, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995;35:233-41.
120. Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, et al. T47Dco cells, genetically instable and containing estrogen receptor mutations, are a model for the progression of breast cancer to hormone resistance. Cancer Res 1990;50:6205-17.
121. Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995;55:3331-8.
122. Karnik PS, Kulkarni S, Liu XP, Budd T, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-53.
123. Madsen MW, Reiter BE, Lykkesfeldt AE. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line. Mol Cell Endocrinol 1995;109:197-207.
124. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 1995;92:4206-10.
125. Raam S, Robert N, Pappas CA, Tamura H. Defective estrogen receptors in human mammary cancers: their significance in defining hormone dependence. J Natl Cancer Inst 1988;80:756-61.
126. Duffy MJ, Duffy GJ. Estradiol receptors in human liver. J Steroid Biochem 1978;9:233-5.
127. Eisenfeld AJ, Aten R, Weinberger M, Haselbacher G, Halpern K, Krakoff L. Estrogen receptor in the mammalian liver. Science 1976;191:862-5.
128. Eisenfeld AJ, Aten RF, Haselbacher GK, Halpern K. Specific macromolecular binding of estradiol in the mammalian liver supernate. Biochem Pharmacol 1977;26:919-26.
129. Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer 1986;57:87-91.
130. Friedman MA, Demanes DJ, Huffman PG. Hepatomas: hormone receptors and therapy. Am J Med 1982;73:362-6.
131. Iqbal MJ, Wilkinson ML, Johnson PJ, Williams R. Sex steroid receptor protein in foetal, adult and malignant human liver tissue. Br J Cancer 1983;48:791-6.
132. Deugnier Y, Ramée MP, Campion JP, Messner M, Launois B, Bourel M, et al. Mise en évidence histochimique de récepteurs de l'œstradiol dans les cancers primitifs du foie. Gastroenterol Clin Biol 1983;7:828-9.
133. Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 1985;89:643-7.
134. Wilkinson ML, Iqbal MJ, Williams R. Characterisation of high affinity binding sites of androgens in primary hepatocellular carcinoma. Clin Chim Acta 1985;152:105-13.
135. Nagasue N, Yukaya H, Chang YC, Ogawa Y, Kohno H, Ito A. Active uptake of testosterone by androgen receptors of hepatocellular carcinoma in humans. Cancer 1986;57:2162-7.
136. Ohnishi S, Murakami T, Moriyama T, Mitamura K, Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 1986;6:440-3.
137. Kohigashi K, Fukuda Y, Imura H. Estrogen receptors in hepatocellular carcinoma: is endocrine therapy for hepatocellular carcinoma likely to be effective ? Gastroenterol Jpn 1987;22:322-30.
138. Nagasue N, Chang YC, Hayashi T, Galiza G, Kohno H, Nakamura T, et al. Androgen receptor in hepatocellular carcinoma as a pronostic factor after hepatic resection. Ann Surg 1989;209:424-7.
139. Nagasue N, Kohno H, Chang YC, Hayashi T, Utsumi Y, Nakamura T, et al. Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. Cancer 1989;63:112-6.
140. Nagasue N, Kohno H, Chang YC, Yamanoi A, Nakamura T, Yukaya H, et al. Clinicopathologic comparison between estrogen receptor-positive and -negative hepatocellular carcinoma. Ann Surg 1990;212:150-4.
141. Eagon PK, Francavilla A, DiLeo A, Elm MS, Gennari L, Mazzaferro V, et al. Quantification of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig Dis Sci 1991;36:1303-8.
142. Nagasue N, Kohono H, Yamanoi A, Kimoto T, Chang YC, Nakamura T. Progesterone receptor in hepatocellular carcinoma. Cancer 1991;67:2501-5.
143. Nakagama H, Gunji T, Ohnishi S, Kaneko T, Ishikawa T, Makino R, et al. Expression of androgen receptor mRNA in human hepatocellular carcinomas and hepatoma cell lines. Hepatology 1991;14:99-102.
144. Nagasue N, Yamanoi A, Kohno T, Chang Y, Taniura H, Uchida M, et al. Androgen receptor in cirrhotic liver, adenomatous hyperplastic nodule and hepatocellular carcinoma in the human. Hepato-gastroenterology 1992;39:455-60.
145. Pacchioni D, Papotti M, Andorno E, Bonino F, Mondardini A, Olivieri F, et al. Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridation. J Surg Oncol 1993;53 (Suppl. 3):14-7.
146. Boix L, Bruix J, Castells A, Fuster J, Bru C, Visa J, et al. Sex hormone receptors in hepatocellular carcinoma: is there a rationale for hormonal treatment ? J Hepatol 1993;17:187-91.
147. Ishizu H, Une Y, Gondo H, Kameda H, Uchino J. Expression of sex hormone receptors and clinicopathological findings in hepatocellular carcinoma. Int J Oncol 1994;4:1349-52.
148. Negro F, Papotti M, Pacchioni D, Galimi F, Bonino F, Bussolati G. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridation. Liver 1994;14:213-9.
149. Galizia G, Nagasue N, Lieto E, Pignatelli C. Recettori per gli androgen e estrogen nell'epatocarcinoma. Valutazione epidemiologica, clinica e prognostica. Chirurgia 1994;7:583-91.
150. Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995;55:498-500.
151. Boix L, Castells A, Bruix J, Solé M, Bru C, Fuster J, et al. Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 1995;22:616-22.
152. Nagasue N, Yu L, Yukaya H, Kohno H, Nakamura T. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 1995;82:542-7.
153. Maudelonde T, Pujol P, Rochefort H. Récepteurs des œstrogènes et cancer du sein. Rev Prat (Paris) 1994;44:1299-303.
154. Petrangeli E, Lubrano C, Ortolani F, Ravenna L, Vacca A, Sciacchitano S, et al. Estrogen receptors: new perspectives in breast cancer management. J Steroid Biochem Mol Biol 1994;49:327-31.
155. Camellini L, Dugani A, Grotola A, Buttafoco P, Merighi A, Ferrari A, et al. Variant liver estrogen receptor (ER) transcripts occur in cirrhotics with liver cell dysplasia (abstract). Hepatology 1995;22:190A.
156. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995;92:39-47.
157. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995;38:2041-9.
158. Fotsis T, Zhang Y, Pepper MS, Adlecreutz H, Montesano R, Nawroth PP, et al. The endogenous œstrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
159. Mishkin SY, Farber E, Ho R, Mulay S, Mishkin S. Tamoxifen alone or in combination with estradiol-17β inhibits the growth and malignant transformation of hepatic hyperplastic nodules. Eur J Cancer Clin Oncol 1985;21:615-23.
160. Mishkin SY, Farber E, Ho RK, Mulay SM, Mishkin S. Evidence for the hormone dependence of hepatic hyperplastic nodules: inhibition of malignant transformation after exogenous 17β-estradiol and tamoxifen. Hepatology 1983;3:308-16.
161. Liao DZ, Porsch-Hällström I, Gustafsson JÅ, Blanck A. Persistent sex differences in growth control of early rat liver lesions are programmed during promotion in the resistant hepatocyte model. Hepatology 1996;23:835-9.
162. Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995;23:712-9.
163. Buckley MMT, Goa KL. Tamoxifen. A reapparaisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-90.
164. Taylor CM, Blanchard B, Zava DT. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 1984;44:1409-14.
165. Charlier C, Chariot A, Antoine N, Merville MP, Gielen J, Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol 1995;49:351-8.
166. Candi E, Melino G, De Laurenzi V, Piacentini M, Guerrieri P, Spinedi A, et al. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 1995;96:141-5.